Stockscreener 앱 받기
10.66
0.02%
-0.0017
Translational Development Acquisition Corp 주식(TDAC)의 최신 뉴스
Translational Development Acquisition Corp. (TDAC) Holds Steady Near Resistance as Trading Volume Remains MutedMcClellan Summation - Newser
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer - NTB Kommunikasjon
TRIANA Biomedicines Adds Veteran Drug Developer Mohan Bala as COO Amid Molecular Glue Push - citybiz
Translational Development Acquisition Corp. Q1 2026 SEC 10-Q Filing: Financial Statements, Management Discussion, and Shareholder Deficit - Minichart
Mountain Crest Acquisition Corp. V 10-Q Q1 2026: Financials, Stockholder Info, and SPAC Operations Update - Minichart
Translational Development Acquisition Corp. 1Q 2026: Net income $1.33M, EPS $0.06— 10-Q Summary - TradingView
Translational Development Acquisition (NASDAQ: TDAC) flags going concern risk as SPAC deadline nears - Stock Titan
TDACW's Earnings Review - Tiger Brokers
Goldman Sachs (NASDAQ: TDAC) reports 6.1% position in TDAC - Stock Titan
Translational Development Acquisition Corp. 2025 Annual Report Amendment: SEC Review, Controls, and Exhibit Certifications - Minichart
Steele Bancorp Inc 2025 Annual Report: Financial Portfolio, Loan Segments, and Credit Assessments Explained - Minichart
Translational Development Acquisition : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Disclosure controls deemed ineffective in TDAC (NASDAQ: TDAC) 10-K/A - Stock Titan
TradingKey - TradingKey
What Translational (TDACW) is doing that smarter investors notice | TDACW Earnings: Translational Reports Zero Revenue, Acquisition Hunt PersistsTop Trending Breakouts - Newser
CEA Industries Announces Board Changes: Tony McDonald Resigns, Carly E. Howard Appointed Chair - Minichart
Translational Development Acquisition Corp. 10-K/A Amendment – SEC Review, Internal Controls, and Nasdaq Listing - Minichart
Key Risks and Business Overview of a Development Stage Telemedicine and Compounding Pharmacy Company - Minichart
UCB to Acquire Candid for Up to $2.2B, Expanding Presence in TCE Antibodies for Immunology - Genetic Engineering and Biotechnology News
Translational Development (NASDAQ: TDAC) seeks up to 12 one‑month extensions - Stock Titan
IMG Pharmaceutical Co Ltd To Acquire Matsumoto Pharmaceutical Co Ltd To Strengthen Integrated Healthcare Platform - BioPharma APAC
TDACW Translational releases no quarterly earnings data as it continues its search for viable SPAC merger targets.Social Trade Signals - Xã Thanh Hà
GSK Completes Acquisition of 35Pharma for $950 Million - Voice of Healthcare
Published on: 2026-04-14 00:50:36 - baoquankhu1.vn
TDAC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Portfolio Update: Can Maywood Acquisition Corp Debt Equity Composite Units deliver consistent dividends2026 Market Trends & Accurate Intraday Trading Signals - baoquankhu1.vn
Tavia Acquisition (NASDAQ:TAVI) Trading 0.1% Higher – Here’s What Happened - Defense World
Translational Development Acquisition (NASDAQ:TDACU) Trading Up 3% – Here’s What Happened - Defense World
Growth Report: Can NTRP expand into new markets2026 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
VION Biosciences Closes Acquisition of CTL, Strengthening Functional Immune Monitoring Capabilities - Business Wire
Is Translational (TDAC) Stock Testing Resistance | Price at $10.59, Up 0.09%Loss Prevention - Cổng thông tin điện tử tỉnh Lào Cai
DYOR PE Ratio & Valuation, Is DYOR Overvalued - Intellectia AI
Spartacus Acquisition Corp. II Warrants (TMTSW) stock price, news, quote and history - Yahoo Finance Singapore
Opendoor Technologies Inc. (OPENW) stock price, news, quote and history - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
Top 10 Organoid Companies - Genetic Engineering and Biotechnology News
Visionary plans anti-aging research hub, health centers with $20M - Stock Titan
TDAC (NASDAQ: TDAC) details 2025 SPAC results, trust balance and June 2026 deadline - Stock Titan
Translational Development Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy - NTB Kommunikasjon
Translational Development Acquisition Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Stock List: Research Stocks from Around the World - GuruFocus
Tavia Acquisition Corp. (TAVI) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Rally Mode: Is Ainos Inc a play on infrastructure spendingWeekly Risk Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Market Review: Can Translational Development Acquisition Corp outperform in the next rallyChart Signals & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio - StreetInsider
TDAC Should I Buy - Intellectia AI
Geopolitics Watch: Is Tapestry Inc a defensive stock2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn
Profit Recap: Is Qiagen NV part of any major indexShare Buyback & Stepwise Trade Execution Plans - baoquankhu1.vn
NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026 - Business Wire
Gains Recap: Is Translational Development Acquisition Corp undervalued by DCF analysisPortfolio Return Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
TDAC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Update: Is Newbury Street II Acquisition Corp affected by consumer sentimentMarket Growth Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
0.40%
0.49%
자본화:
|
볼륨(24시간):